Intratracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia

2015279 citationsJournal Article

Authors

Tsu F. Yeh · Maternal Child and Family Health

Chung M. Chen · Taipei Medical University Hospital

Shou Yien Wu · John H. Stroger, Jr. Hospital of Cook County

Zahid Husan · John H. Stroger, Jr. Hospital of Cook County

Tsai C. Li · College of Healthcare Management

Wu‐Shiun Hsieh · National Taiwan University Hospital

Chang Hai Tsai

Abstract

In very-low-birth-weight infants with severe respiratory distress syndrome, intratracheal administration of surfactant/budesonide compared with surfactant alone significantly decreased the incidence of BPD or death without immediate adverse effect. Clinical trial registered with www.clinicaltrials.gov (NCT-00883532).

Topics & Keywords

Neonatal Respiratory Health Research Respiratory Support and Mechanisms Congenital Diaphragmatic Hernia Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: American Journal of Respiratory and Critical Care Medicine

Volume 193, Issue 1, pp. 86-95

DOI: 10.1164/rccm.201505-0861oc

Field-Weighted Citation Impact: 17.73